Stockpolly
Search
ANNX · NASDAQ · Biotechnology

Annexon (ANNX)

Develops C1q-targeted therapies for complement-mediated diseases of the body, eye, and brain.

$4.96
Pre-market+0.02 (+0.41%)
At close$4.94(+0.92%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000110
Gross profit000000000−1−10
353029343952575257494557
Research & development282321253043484450433647
77889797781011
General & administrative77889797781011
Other expenses000103010−2−10
Operating income−35−30−29−34−39−52−57−52−57−50−46−57
223454332222
Interest income223454332−820
Other non-operating income0−2−3−4−5−4−3−3−2−2−2−2
Income before tax−32−28−25−30−35−49−54−49−55−48−44−55
Net income from continuing operations−32−28−25−30−35−49−54−49−55−48−44−55
Net income−32−28−25−30−35−49−54−49−55−48−44−55
EPS, basic−$0.43−$0.36−$0.21−$0.23−$0.25−$0.33−$0.37−$0.34−$0.37−$0.28−$0.23−$0.28
EPS, diluted−$0.43−$0.36−$0.21−$0.23−$0.25−$0.33−$0.37−$0.34−$0.37−$0.28−$0.23−$0.28
Weighted average shares, basic7578123130140148148148149155194201
Weighted average shares, diluted7578123130140148148148149155194201
EBITDA−34−27−25−29−34−48−54−49−54−47−43−55
Depreciation & amortization111111111111
EBIT−35−28−25−30−35−49−54−49−55−48−44−55